MedTrace Logo

Impact of Pre-operative Bevacizumab on Complications After Resection of Colorectal Liver Metastases

NCT00875147 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 163

Last updated 2016-10-25

No results posted yet for this study

Summary

Hypothesis of the study: Neoadjuvant chemotherapy with Bevacizumab impairs postoperative outcome after resection of colorectal liver metastases.

Conditions

  • Colorectal Liver Metastases

Interventions

DRUG

bevacizumab

Neoadjuvant chemotherapy with bevacizumab

Sponsors & Collaborators

  • University of Zurich

    lead OTHER

Principal Investigators

  • Stefan Breitenstein, MD · Departement of Visceral and Transplantation Surgery of University hospital of Zurich

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-04-30
Primary Completion
2009-08-31
Completion
2009-09-30

Countries

  • France
  • Spain
  • Switzerland

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00875147 on ClinicalTrials.gov